US20060110815A1 - Personal care composition containing ozone-stressed yeast lysates - Google Patents

Personal care composition containing ozone-stressed yeast lysates Download PDF

Info

Publication number
US20060110815A1
US20060110815A1 US11/248,522 US24852205A US2006110815A1 US 20060110815 A1 US20060110815 A1 US 20060110815A1 US 24852205 A US24852205 A US 24852205A US 2006110815 A1 US2006110815 A1 US 2006110815A1
Authority
US
United States
Prior art keywords
ozone
yeast
personal care
care composition
stressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/248,522
Other languages
English (en)
Inventor
James Gruber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Personal Care Products LP
Original Assignee
Arch Personal Care Products LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Personal Care Products LP filed Critical Arch Personal Care Products LP
Priority to US11/248,522 priority Critical patent/US20060110815A1/en
Priority to JP2007536849A priority patent/JP5687817B2/ja
Priority to PCT/US2005/036717 priority patent/WO2006044482A2/en
Priority to EP05810335.9A priority patent/EP1807828B1/de
Assigned to ARCH PERSONAL CARE PRODUCTS, L.P. reassignment ARCH PERSONAL CARE PRODUCTS, L.P. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRUBER, JAMES VINCENT
Publication of US20060110815A1 publication Critical patent/US20060110815A1/en
Priority to JP2013154099A priority patent/JP2013224328A/ja
Priority to US15/236,355 priority patent/US10285933B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/063—Lysis of microorganisms of yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95

Definitions

  • This invention relates generally to personal care compositions, and more specifically to such compositions containing ozone-stressed yeast lysates.
  • Ozone is increasingly becoming recognized as a detrimental agent for skin cells. Ozone can affect lipids, proteins, nucleic acids and sugars but is especially severe to key antioxidants located in skin cells. The damage appears to be most severe at the surface layers of skin, and diminishes as one probes into deeper dermal and epidermal layers. Ozone, which is generated by a number of natural sources such as lightning, is also generated by various industrial sources, such as the burning of fossil fuels, and in particular, the emission from automobiles, which are a leading cause of urban smog. Ozone is formed when reactive oxygen radicals combine with oxygen gas to form a molecule that contains three moles of oxygen as can be seen in the empirical equation: O 2 +O ⁇ O 3
  • ozone will diminish the amounts of vitamins C and E in the upper layers of the stratum corneum as well as oxidize key lipids in the bi-layer of the stratum corneum.
  • ozone has been implicated in protein and nucleic acid damage as well. Thiele, J J. et al., “In-Vivo Exposure to Ozone Depletes Vitamins C and E and Induces Lipid Peroxidation in Epidermal Layers of Murine Skin” Free Rad. Biol. Med. 23, 385-391 (1997). Vitamins C and E are key natural antioxidants that offer important defense mechanisms against the ravages of ozone to the deeper layers of the skin.
  • the lipid bi-layer is the most important physical barrier between the interior of the human body and external elements. Deterioration of the lipid bi-layer increases trans-epidermal water loss and leads to drying and cracking of the skin.
  • Methods to measure the effects of ozone stress on human skin and human skin-mimics are disclosed in Cotovio, J. et al., “Generation of oxidative stress in human cutaneous models following in-vitro ozone exposure,” 15, 357-362 (2001) and Weber, S U. et al., “High-Performance Liquid Chromatography Analysis of Ozone-Induced Depletion of Hydrophilic and Lipophilic Antioxidants in Murine Skin,” Method Enzy., 319, 536-546 (2000).
  • melanin is a key photo-protective pigment located in the skin and hair that has not previously been shown to be a target for ozone degradation.
  • Other key cutaneous lipids that ozone can attack include cholesterol, cholesterol esters, free fatty acids and ceramides that make up the lipid bilayers of the skin.
  • Damage to nucleic acids can lead to cellular mutations and apoptosis of important skin cells.
  • skin cells include, but are not limited to fibroblasts, keratinocytes, dermal papilla, melanocytes, macrophages, corneocytes, Langerhan cells, neutrophils, adipocytes, sebocytes, and nerve cells which reside at the surface of the skin.
  • ozone can deteriorate proteins and sugars that comprise the extracellular matrix and natural moisturizers in the skin.
  • yeast respond to the presence of ozone.
  • High concentration of ozone is typically lethal to yeast.
  • lower concentrations of ozone may not only be nonlethal, but may also influence the yeast to increase production of certain proteins, including glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
  • GAPDH is a key “housekeeper” enzyme that is responsible for oxidatively converting glyceraldehyde-3-phosphate into 1,3-diphosphoglycerate in human skin as part of the glucose cellular enzymatic pathways. It is known that the enzymatic activity of GAPDH is affected by oxidative stress and ultraviolet light. Hinze, H et. al., “Effect of ozone on ATP, cytosolic enzymes and permeability of Saccharomyces cerevisiae,” Arch Microbiol. 147, 105-108 1987.
  • yeast and derivatives thereof has become quite popular in topical cosmetic and therapeutic applications.
  • active yeast lysates have been sold in the personal care industry for many years. Historically, these products have been marketed and sold as activators of tissue oxygen uptake. It has been found that stressed yeast lysates will stimulate growing cells to increase their oxygen consumption. Additionally, it has been discovered that yeast tissue respiratory factors could also stimulate collagen production in skin.
  • U.S. Pat. No. 2,239,345, issued April, 1941 discloses a method for improving the uptake of oxygen in living yeast cells by application of components derived from yeast.
  • U.S. Pat. No. 5,057,320, issued October, 1991 discloses yeast compositions containing picolinic acid to increase oxygen uptake in living mammalian skin cells.
  • U.S. Pat. No. 5,514,591, issued May, 1996 discloses improved methods to measure the ability of yeast extracts to stimulate oxygen uptake in human skin cells.
  • Despite previous attempts to increase oxygen uptake in human skin cells there is no solution that directly addresses the need of ozone protection for the skin.
  • Saccharomyces cerevisiae more commonly known as Baker's Yeast, respond well to growth stresses, such as heat shock, ozone, peroxides and ultraviolet light. Surprisingly, the stress provides enhanced production of stress response agents, or protective cell components in the yeast. These stress response agents have therapeutic effects on human skin cells.
  • One aspect of the invention relates to an ozone-stressed yeast lysate produced by a method including the steps of: exposing growing yeast to an ozone concentration sufficient to produce ozone-stressed yeast; lysing the ozone-stressed yeast to produce an ozone-stressed yeast lysate comprising water-soluble and water-insoluble components; and separating the water-soluble components from the water-insoluble components to produce an ozone-stressed yeast lysate comprising the water-soluble components.
  • a personal care composition including: an ozone-stressed yeast lysate and a preservative, wherein the preservative is selected from the group consisting of alcohol, glycol, parabens, hydantoins, quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing agents, halogenated compounds, and combinations thereof.
  • a further aspect of the invention relates to a composition for topical treatment of skin, including the ozone-stressed yeast lysate described above and a cosmetically acceptable vehicle for application to the skin.
  • Yet another aspect of the present invention relates to a method for preparing a personal care composition including an ozone-stressed yeast lysate effective in reducing or minimizing ozone-induced skin degradation when applied to skin cells.
  • the method includes the steps of: growing yeast in a fermentation broth; exposing the yeast to ozone by aerating the yeast for a time period of between about five minutes and about seventy-two hours with an aeration gas having an ozone concentration of from about 0.0001 millimole (mM) to about 1.0 millimole (mM) based on the total volume of the fermentation broth to produce ozone-stressed yeast; lysing the ozone-stressed yeast to produce an ozone-stressed yeast lysate; and incorporating the ozone-stressed yeast lysate into a personal care composition.
  • mM millimole
  • mM millimole
  • FIG. 1 is a color photograph of the results from ozone exposure to water, non-ozone-stressed yeast lysate and ozone treated yeast lysate using an ozone reactive dye as an indicator of ozone degradation.
  • a yeast lysate is a composition derived from yeast grown on a nutritional growth media that is subsequently killed in such as way as to afford a product that includes cellular yeast components including, but not limited to, the nutrient broth, cellular protein material, cellular nuclear material, cellular cytoplasmic material, cellular protoplasmic material and/or cell wall components.
  • cellular yeast components including, but not limited to, the nutrient broth, cellular protein material, cellular nuclear material, cellular cytoplasmic material, cellular protoplasmic material and/or cell wall components.
  • the yeast lysate is essentially water-soluble.
  • water-soluble means 0.1 gram of yeast components that are dissolved in 1 gram of water.
  • an ozone-stressed yeast is a yeast that has undergone exposure to ozone, otherwise referred to as “ozone treatment”.
  • An ozone-stressed yeast lysate is a lysate of the ozone-stressed yeast.
  • yeast is meant to encompass a single yeast cell, multiple yeast cells, and/or a culture of yeast cells.
  • the yeast of the present invention can be of various genus known to those skilled in the art including, but not limited to: Arthroascus, Aureobasidium, Botryoascus, Brettanomyces, Candida, Citeromyces, Clavispora, Cryptococcus, Debaryomyces, Dekkera, Filobasidium, Guilliermondella, Hansenula, Haneseniaspora, Hormoascus, Klockera, Kluyveromyces, Leucosporidium, Lipomyces, Malassezia, Metschnikowia, Nadsonia, Nematospora, Oosporidium, Pachysolen, Pachytichospora, Penicillium, Pichia, Prototheca, Rhodosporidium, Rhodotorula, Saccharomyces, Saccharomycodes, Saccharomycopsis, Schizosaccharomyce, Schwanniomyces, Sporobolomyces, Spo
  • the yeast is grown on growth media which has peptone and other common growth media ingredients.
  • An example of preferred growth media called “yeast fermentation media,” can be found in the “Handbook of Microbiological Media,” published by CRC Press.
  • yeast can be grown simply in an open-air fermentation vessel, or by using a sealed biological fermentor, available from New Brunswick Scientific, Edison, N.J.
  • ozone generators used for the ozone treatment of the yeast can be found at, for example, Erwin Sander Elektroapparatebau GmbH, Uetze-Eltze, Germany. Preferably, the ozonizer Model IV from Sander is used. In most circumstances, an ozone detector is used in addition to the ozone generator. Suitable ozone detectors are available from Dasibi, Glandale, Calif.
  • the yeast is grown in an environment that contains an effective amount of ozone.
  • Saccharomyces cerevisiae is grown with aeration at 30° Celsius.
  • An effective amount of ozone is an amount that is sufficient to cause a yeast response, yet is sub-lethal.
  • sub-lethal it is meant that at least 1% of the yeast survive after being exposed to ozone. Therefore, the amount of ozone applied to yeast should allow at least 1% to survive.
  • the amount of ozone applied to the yeast may allow at least 10% of the yeast to survive the treatment.
  • the amount of ozone applied to the yeast should allow at least 50% of the yeast to survive the treatment.
  • the amount of ozone applied to the yeast should allow at least 80% of the yeast to survive the treatment.
  • the ozone may be introduced to the yeast in any method effective to expose the yeast to the ozone.
  • the ozone may be introduced to the yeast through an aeration gas which includes the ozone and either air or oxygen.
  • the aeration gas is usually at a temperature between about 15° Celsius and about 90° Celsius.
  • the yeast are exposed to a concentration of ozone for a time period sufficient to obtain a maximum amount of yeast that have produced cellular components effective against degradation of skin cell components.
  • the yeast may be exposed to the ozone for several minutes to several days depending on yeast type, ozone concentration, aeration rates, temperature, and like.
  • the yeast is exposed to an ozone concentration between about 0.0001 millimole (mM) to about 1.0 mM for a period of 5 minutes to 72 hours.
  • the yeast is exposed to an ozone concentration between about 0.01 mM and about 0.8 mM for a period of about 10 minutes to about 60 minutes.
  • the yeast is exposed to a concentration of ozone between about 0.1 mM and about 0.5 mM for a period of from about 15 minutes to about 30 minutes.
  • the yeast when the yeast is exposed to ozone for a lengthier period of time it is suitable that the yeast is exposed to a lower concentration of ozone.
  • the yeast when the yeast is exposed to ozone for a shorter period of time it is suitable that the yeast is exposed to a higher concentration of ozone.
  • the ozone-stressed yeast respond to the presence of ozone by generating protective agents that counteract the detrimental effects of ozone.
  • the ozone-stressed yeast is then lysed to obtain ozone-stressed yeast lysate.
  • the yeast can be lysed by a variety of methods known to one skilled in the art, including but not limited to, enzymes, high-speed agitation, changes in growth media, autolysis or changes in pH.
  • the ozone-stressed yeast lysate typically contains water-soluble and water-insoluble components. The water-insoluble components may be separated from the water-soluble components.
  • the ozone-stressed yeast lysate may be filtered and purified to remove cellular bodies, odor and other undesirable materials.
  • the ozone-stressed yeast lysate is tested to determine whether it is suitable for cosmetic use.
  • Preferably two-dimensional polyacrylamide gel electrophoresis is performed, and the proteins present in the ozone-stressed yeast lysate are quantified.
  • the ozone-stressed yeast responds to the presence of the ozone by generating protective agents or cellular components, which are capable of counteracting the detrimental effects of ozone. It is possible to determine which proteins are produced by the ozone-stressed yeast by running a yeast gene microarray to determine which genes in the yeast are up-regulated or down-regulated as a result of the ozone treatment.
  • yeast gene microarrays allows comparison of changes that occur in yeast when different stresses, such as hydrogen peroxide, UV and ozone, are placed on the yeast. Gene microarrays are useful in demonstrating the differences these stresses can have on the proteins expressed by stimulating the growing yeast. Saccharomyces cerevesiae gene microarray chips are available from MWG Biotech (High Point, N.C.).
  • the ozone-stressed yeast lysates may be further purified by any number of means known to those skilled in the art including, but not limited to, chromatography, steam distillation, solvent extraction, centrifugation, decantation, filtration, or carbon treatment.
  • the lysates of the present invention may be further concentrated by any means known to those skilled in the art including, but not limited to, evaporation, spray-drying, lyophylization, steam distillation or belt or drum drying.
  • the ozone-stressed yeast lysates may be used in personal care compositions. Such personal care compositions may provide skin cells with protection from ozone pollution or skin cell component degradation associated with exposure to ozone. Specifically, the addition of ozone-stressed yeast lysates may control the breakdown of vitamins C and E, DNA, RNA and bilayer lipids, which occurs in skin cells exposed to ozone.
  • the personal care composition of the present invention may contain an effective amount of ozone-stressed yeast lysate and at least one preservative selected from the group consisting of alcohols, glycols, parabens, quaternary nitrogen-containing compounds, isothiazolinones, aldehyde-releasing agents, antioxidants and halogenated compounds.
  • Illustrative alcohols include phenoxyethanol, isopropyl alcohol, and benzyl alcohol; illustrative glycols include propylene, butylene, and pentylene glycol; illustrative parabens (also known as parahydroxybenzoic acids) include methyl, propyl and butyl-parabens; illustrative quaternary nitrogen-containing compounds include, benzalkonium chloride, and Quaternium 15; illustrative isothiazolinones include methylisothiazolinone and methylchloroisothiazolinone; illustrative aldehyde-releasing agents include DMDM hydantoin, imidazolidinyl urea and diazolidinyl urea; illustrative antioxidants include butylated hydroxytoluen and tocopherol, and illustrative halogenated compounds include triclosan, and chlorohexidine digluconate.
  • preservatives useful for the purposes of the present invention can be found, for example, in Steinberg, D. “Frequency of Use of Preservatives 2001” Cosmet. Toilet. 117, 41-44, (2002) and, “Preservative Encyclopedia” Cosmet. Toilet. 117, 80-96 (2002).
  • An effective amount of ozone-stressed yeast lysate is an amount of ozone-stressed yeast lysate that provides skin cells with adequate protection from exposure to ozone. Adequate protection may be provided by utilizing a concentration of ozone-stressed yeast lysate in a personal care composition that is sufficient to impart efficacy against ozone damage to at least a portion of the skin cells that are exposed to ozone present in the environment. The effective amount of the ozone-stressed yeast lysate is provided by incorporating the ozone-stressed yeast lysate into a personal care composition.
  • the amount of ozone-stressed yeast lysate is present in a personal care composition between 0.001% and 100% based on the weight of the personal care product. More preferably the ozone-stressed yeast lysate is present in the personal care composition in an amount between about 0.01% and about 50% based on the total weight of the personal care composition. Alternatively the ozone-stressed yeast lysate can be present in the personal care composition between about 1% and about 10% based on the total weight of the personal care composition.
  • the personal care composition can optionally contain other functional ingredients such as, water, surfactants, emulsifiers, conditioners, emollients, waxes, oils, polymers, thickeners, fixatives, colorants, humectants, moisturizers, stabilizers, diluents, solvents, fragrances and the like, as well as active ingredients such as, for example, botanicals, neutraceuticals, cosmeceuticals, therapeutics, pharmaceutics, antifungals, antimicrobials, steroidal hormones, antidandruff agents, anti-acne components, sunscreens, preservatives and the like.
  • functional ingredients such as, water, surfactants, emulsifiers, conditioners, emollients, waxes, oils, polymers, thickeners, fixatives, colorants, humectants, moisturizers, stabilizers, diluents, solvents, fragrances and the like.
  • active ingredients such as, for example
  • the ozone-stressed yeast lysate can be used in various types of cosmetic formulations including, but not limited to, lotions, ointments, creams, sprays, spritzes, aqueous or aqueous alcoholic mixtures, gels, mousses, patches, pads, masks, moistened cloths and wipes, solid sticks, clear sticks, lipsticks, aerosol creams, anhydrous powders, talcs, tonics, oils, emulsions, and bath salts.
  • Such cosmetic formulations may be used as topical treatments for skin.
  • the ozone-stressed yeast lysates of the present invention may include the lysates alone or they may include the yeast lysates encapsulated in various chemical delivery vehicles known to those skilled in the art.
  • Such cosmetically acceptable delivery vehicles include, but are not limited to, liposomes, niosomes, sub-micron emulsions, polymeric encapsulants, gels, creams, lotions, and combinations thereof.
  • the organism used in this study was S. cerevisiae (Red Star baker's yeast). Stock culture was maintained on a yeast peptide dextrose (YPD) agar slant (Difco). The working culture was maintained in YPD broth at 4° C. The fermentation was carried out with the medium containing 10 g/L yeast extract, 8 g/L NH 4 SO 4 , 3 g/L KH 2 PO 4 , 2 g/L MgSO 4 , and 0.5 mL/L Antifoam A. Unless otherwise stated, the working volume for fermentation was 2 liters (L).
  • a New Brunswick Bioflo 110 benchtop bioreactor (Edison, N.J.) equipped with automatic pH, temperature, agitation, dissolved oxygen (DO) and antifoam controls was used.
  • the 2-L vessel was equipped with air in- and out-ports, alkali and medium addition ports, and effluent side ports.
  • Medium pH was maintained at 5.5 by adding 4 M NaOH and/or 4 M H2SO4.
  • Aeration was maintained at 1 vvm (volume of air/working volume of fermentor/min) and DO level was kept at 60% by cascading to the agitation.
  • the fermentor was fed with 250 g/L of glucose solution at the rate of 1.2 mL/h.
  • Ozone gas was produced from purified extra dry air by an ozone generator (Model Lab2B Ozonia, Elmwood Pk, N.J.). The inlet airflow rate was maintained at 0.5 L/min. The ozone generator was set to produce 0.5 g/h of ozone. The ozone-air stream from the ozone generator was mixed with 1.5 L/min of air. The mixture of ozone and air (0.5 part/1.5 part) was purged in to the fermentation medium. Ozone concentration was measured using indigo dye (see FIG. 1 ) and/or a UV spectroscopic method that indicates ozone at a frequency of 258 nm. All experimental work with ozone was done under a chemical hood. An activated carbon column absorbed excess ozone.
  • Samples of S. cerevisiae for analytical tests were taken from fermentation broth after 48 hours at 1.0 ⁇ 10 9 cells/mL. Forty-five milliliters (mL) of culture sample were centrifuged (15000 rpm for 10 min) and washed with distilled water. The precipitate was resuspended in 45 mL of 10 mM phosphate buffer of pH 7, supplemented with phenylmethylsulphonyl fluoride (Sigma Chemical Co., St. Louis, Mo.) to 1 mM and pepstatin A (Sigma) to a concentration of 10 ⁇ M. Forty five mL glass beads (0.5 mm diameter; Biospec Products, USA) were added to the cell suspension.
  • the suspension in 90 mL container, was inserted into a Beadbeater (Biospec Products) and shaken at homogenization speed for 3 min.
  • the sample chamber was cooled during the homogenization step by an ice bath.
  • the protein concentration of samples was determined by BCA protein assay (Sigma). Samples of each lysate were analyzed as described below.
  • Two-dimensional electrophoresis was performed according to the method of O'Farrell (J. Biol. Chem. 250: 4007-4021, 1975) by Kendrick Labs, Inc. (Madison, Wis.) as follows: Isoelectric focusing was carried out in glass tubes of inner diameter 2.0 mm using pH 4-8 2.0% ampholines (Gallard Schlesinger Industries, Inc. Garden City, N.Y.) for 9600 volt-hrs. Fifty nanograms of an IEF internal standard, tropomycin, was added to each sample. Tropomycin shows two polypeptide spots of similar pI (ionic charge); the lower spot of MW 33,000 and pI 5.2 was marked with an arrow on the stained gels. The tube gel pH gradient plot for this set of ampholine was determined with a surface pH electrode.
  • each tube gel was sealed to the top of a stacking gel that was on top of a 12% acrylamide slab gel (0.75 mm thick).
  • SDS slab gel electrophoresis was carried out for 4 hours at 12.5 mA/gel.
  • the following proteins from Sigma were added as molecular weight standards to the agarose that sealed the tube gel to the slab gel: myosin (220,000), phosphorylase A (94,000), catalase (60,000), actin (43,000), carbonic anhydrase (29,000) and lysozyme (14,000). These standards appear along the basic edge of the silver-stained 12% acrylamide slab gel.
  • Duplicate gels were obtained by the 2-D methodology as described above.
  • One gel from each pair was scanned with a laser densitometer (Model PDSI, Molecular Dynamics Inc, Sunnyvale, Calif.). The scanner was checked for linearity prior to scanning with a calibrated Neutral Density Filter Set (Melles Griot, Irvine, Calif.).
  • the images were analyzed using Progenesis Discovery software (version 2003.3, Nonlinear Technology) such that all major spots and all changing spots were outlined, quantified and matched on all the gels.
  • the general method of computerized analysis for these pairs included automatic spot finding and quantification, automatic background subtraction (Progenesis algorithm) and automatic spot matching in conjunction with detailed manual checking of the spot finding and matching functions.
  • results from computerized comparison are given in fold increase or decrease (difference) of the polypeptides for non-treated sample versus 15 min ozone-treated and non-treated versus 45 min ozone treated sample. The differences are calculated from spot percentages (individual spot density divided by total density of all measured spots). Increased (up-regulated) and decreased (down-regulated) polypeptide spots with a fold difference of ⁇ 3 were taken into consideration.
  • the term “up-regulated” implies that a protein has been over-expressed, while the term “down-regulated” implies that the protein has been under-expressed.
  • Table 1 Summary of proteins only present in non-treated yeast lysate and not present in yeast lysate treated for 15 minutes with ozone.
  • Table 2 Summary of proteins only present in 15 minute ozone treated yeast lysate and not present in non-treated yeast lysate.
  • Table 3 Summary of proteins up-regulated (i.e., present but increased) in 15 minute ozone-stressed yeast lysate but not increased in non-treated yeast lysate.
  • Table 4 Summary of proteins down-regulated (i.e., present but diminished) in 15 minute ozone-stressed yeast lysate but not diminished in non-treated yeast lysate.
  • Table 7 Summary of proteins up-regulated (i.e., present but increased) in 45 minute ozone-stressed yeast lysate but not increased in non-treated yeast lysate.
  • yeast was exposed to either ozone or hydrogen peroxide for the same length of time. The yeast was then subjected to microarray analysis to determine what genes were up-regulated and which were down-regulated as a result of the treatments. The following test protocols were employed in this study.
  • yeast cells are difficult to lyse it was necessary to monitor the process to make sure that the nucleic acids were being released. After briefly mixing the sample, an initial 2 ⁇ l aliquot was obtained and diluted with 1 ml of nuclease free water. This sample was read at 260 nm and served as a “baseline” measurement for free nucleic acids. The remaining untested sample was then vigorously vortexed at 1-minute intervals. After each interval, a 2 ⁇ l aliquot was prepared and read as described above. As the yeast cells were lysed, the absorbance of the aliquot at 260 nm increased and then leveled off as the lysis process was completed. Total lysing normally occurs within 2-5 rounds of vortexing. After completing the lysis process for each sample, the samples stored on dry ice (approximately ⁇ 75° C.) until analysis was possible.
  • the filter was then washed to remove any residual cellular debris from the RNA bound to the glass fibers applying 700 ⁇ l of wash solution 1 (1 time) and 500 ⁇ l of wash solution 2 (2 times) to the filter cartridge and centrifuging at 14,000 RPM for 1 minute to pass each wash through the cartridge. After each wash the flow through was discarded. After the final wash one final spin was performed without wash solution to remove any residual wash solution in the filter cartridge.
  • the RNA bound to the glass fibers within the cartridge was then eluted by applying 30 ⁇ l of Tris-EDTA buffer (10 mM Tris-HCl, 1 mM EDTA, preheated to 70-80° C.) to the cartridge and centrifuging the cartridge in a new collection tube at 14,000 RPM for one minute.
  • RNA Concentration Assay (Molecular Probes Ribogreen Assay, Eugene, Oreg.)
  • the Ribogreen reagent was provided as a stock solution in DMSO. Prior to use the reagent was diluted 2000 fold in TE buffer. The RNA assay requires 200 ⁇ l of diluted Ribogreen reagent per sample to be tested and 1 ml of the reagent for the standards. Once prepared the diluted reagent was stored protected from light. A series of RNA standards were prepared by diluting purified ribosomal RNA derived from E. coli to the following concentrations: 2 ⁇ g/ml, 1 ⁇ g/ml, 200 ng/ml, 40 ng/ml and 0 ng/ml (blank). Prior to assaying, the RNA samples prepared above were diluted 1000 fold in TE buffer.
  • RNA assay 100 ⁇ l of the diluted samples or standards were transferred to the wells of a black 96-well plate. The samples and standards were assayed in duplicate. After the samples/standards were added to the plate 100 ⁇ l of the diluted Ribogreen assay reagent was added to the wells and the plate was gently mixed and allowed to incubate for 5-10 minutes protected from the light. After this incubation the plate was read with a fluorometer using an excitation wavelength of 500 nm and an emission wavelength of 525 nm.
  • a 1% RNA gel was prepared by adding 0.3 g agarose to 21.6 ml diethylpyrocarbonate (DEPC) treated water.
  • the agarose was dissolved by boiling the water in a microwave oven. After the solution was cooled to approximately 55° C. 5.4 ml of formaldehyde and 3.0 ml 10 ⁇ MOPS (0.2 M MOPS [pH 7.0], 20 mM sodium acetate, 10 mM EDTA, made in DEPC H 2 O and filter sterilized) was added. After mixing, the agarose gel was cast in the horizontal gel apparatus with the loading slots placed on the side of the gel closest to the negative terminal. The gel was allowed to set for at least 1 hour at room temperature.
  • DEPC diethylpyrocarbonate
  • RNA samples were prepared by transferring ⁇ 1 ⁇ g of each sample RNA to a 600 ⁇ l PCR tube. DEPC H 2 O was used to bring the total volume of all the samples to a common level and then 1-3 volumes of a gel-loading buffer (i.e.
  • RNA sample was used for subsequent processing if both the 18 S and 28S ribosomal bands were clearly visible and there was little or no staining below the 18 S band.
  • First Strand cDNA Synthesis To start the first strand synthesis, 5 ⁇ g of total RNA for each sample was added to 600 ⁇ l PCR tubes and the total volume of liquid in the tube was adjusted to 12 ⁇ l with DEPC H 2 O. To each tube, 1 ⁇ l of T7 Oligo(dT) primer was added and the tube was incubated at 70 ⁇ 2° C. for 10 minutes to denature the RNA and then placed on ice to allow the primer to anneal to the poly A ends of the mRNA. After cooling 2 ⁇ l of 10 ⁇ first strand buffer, 1 ⁇ l of RNAse inhibitor and 4 ⁇ l of dNTP Mix was added to each tube, and the tube was placed at 42° C.
  • Second Strand Synthesis and cDNA Purification For the synthesis of the second strand of cDNA the following items was added to the tubes above (in this order): 63 ⁇ l DEPC H 2 O, 10 ⁇ l 10 ⁇ second strand buffer, 4 ⁇ l dNTP mix, 2 ⁇ l DNA Polymerase and 1 ⁇ l of RNAse H. The tube was mixed and then incubated at 16 ⁇ 2° C. for 2 hours. Towards the end of the 2 hour incubation a sufficient quantity of DEPC H 2 O was warmed to 50 ⁇ 2° C. and a cDNA purification filter cartridge was equilibrated with 50 ⁇ l of cDNA binding buffer (one cartridge per sample) for at least 5 minutes.
  • cDNA binding buffer 250 ⁇ l was added to each tube and thoroughly mixed.
  • the contents of the PCR tube was transferred to the cDNA purification filter cartridge.
  • the cartridge was placed in a collection tube and centrifuged at 10,000 RPM for 1 minute.
  • the flow-through was discarded and 650 ⁇ l of cDNA wash solution was added to the cartridge.
  • the cartridge was centrifuged again and the flow-through was discarded, and then centrifuged one last time to ensure that the wash buffer was completely emptied from the filter.
  • the cDNA was eluted by applying 10 ⁇ l of preheated DEPC H 2 O to the filter and centrifuging the filter in a new collection tube at 10,000 RPM for one minute. This elution was performed one additional time to give a total volume of 16-18 ⁇ l of cDNA solution.
  • the in vitro transcription began by adding the following to the cDNA solution: 4 ⁇ l each of T7 ATP solution, T7 CTP solution, T7 GTP solution, T7 UTP solution, 4 ⁇ l of 10 ⁇ Reaction buffer, and 4 ⁇ l of T7 enzyme mix. The tube was mixed and then incubated at 37 ⁇ 2° C. for 6-14 hours. Towards the end of the incubation a sufficient volume of Elution Solution was warmed to 50-60° C. and an aRNA filter cartridge was equilibrated with 100 ⁇ l of aRNA binding buffer for at least 5 minutes.
  • aRNA binding buffer was added to the sample tubes and thoroughly mixed. An additional 250 ⁇ l of absolute ethanol was added to each tube. The mixture was then transferred to an aRNA filter cartridge; the cartridge was inserted into a collection tube and centrifuged at 10,000 RPM for 1 minute. The flow-through was discarded and 650 ⁇ l of aRNA wash buffer was added to the cartridge followed by centrifuging at 10,000 RPM for one minute. After discarding the flow through the cartridge was spun one final time to remove all traces of the wash buffer. The cartridge was transferred to a new collection tube and 25 ⁇ l of prewarmed Elution Solution was added to the cartridge.
  • the cartridge was incubate for 2 minutes at room temperature and then aRNA was eluted by centrifuging for 1 minute at 10,000 RPM. This elution was performed one additional time to give a total volume of 45-50 ⁇ l of aRNA solution.
  • the final concentration of the aRNA was determined by the Ribogreen assay as described above.
  • the quality of the aRNA was checked via gel electrophoresis as described above. An aRNA sample was used for subsequent processing if a broad band of RNA was observed.
  • the tubes were incubated for 15 minutes at 85 ⁇ 2° C. At the end of the 15 minutes the tubes were placed on ice to cool and then add 2.5 ⁇ l of ASAP stop solution was added to each tube. The proportions given here were enough for analyzing one microarray chip.
  • a microcon YM-30 filter column was inserted into a collection tube and filled with 400 ⁇ l of TE buffer.
  • the Cy3 and Cy5 probes was combined (12.5 ⁇ l of each) and then added to the microcon filter and thoroughly mixed with the TE buffer.
  • the filter was centrifuged at 12,000 RPM for 8 minutes and the flow through was discarded.
  • the column was washed twice with 400 ⁇ l of TE buffer, discarding the flow though each time. After the final wash the filter column was inverted, and placed into a new collection tube and centrifuged at 12,000 RPM for 2 minutes to collect the probe (the probe was concentrated in a volume of 2-30 ⁇ l of residual TE buffer).
  • the hybridization mixture (approximately 450 ⁇ l) was applied to the glass gasket slide and a Yeast Microarray Chip (High Point, N.C.) was placed face down on top of this gasket such that the hybridization solution was sandwiched between the glass gasket slide and the microarray face of the chip.
  • the top half of the chamber was then attached and the connecting thumbscrew tightened. After verifying that there was good bubble formation in the chamber, it was placed into the hybridization oven for approximately 17 hours (60° C. and rotating at 4 RPM).
  • the microarray/glass gasket was removed from the SUREHYB chamber and placed in 50 ml of wash solution 1 (room temperature, 6 ⁇ SSC, 0.005% Triton X-102). After the gasket had fallen away from the microarray, the array was transferred to 300 ml of fresh wash solution on a magnetic stir plate. The array was washed while the solution was mixed at medium speed for 10 minutes and then transferred to 300 ml of wash solution 2 (0.1 ⁇ SSX, 0.005% Triton X-102, 4° C.) for 5 minutes. After the final wash the array was centrifuged at 500 RPM for 5 minutes to dry it.
  • wash solution 1 room temperature, 6 ⁇ SSC, 0.005% Triton X-102
  • wash solution 2 0.1 ⁇ SSX, 0.005% Triton X-102, 4° C.
  • microarrays were scanned with an Axon GenePix 4100A Scanner with the scanning gains for the scanner were adjusted such that the cy5/cy3 image count ratios were between 0.88 and 1.12.
  • the level of gene expression was related to the fluorescence intensity of the probed gene marker on the microarray. Since it is possible to have differences in labeling efficiency when making the Cy3 and Cy5, probes it is typical to normalize the fluorescence measurements between the two respective dyes before looking at changes in gene expression. Fluorescence intensities for the microarrays were subjected to global normalization. The total fluorescent signal for both dyes was normalized with a correction factor that would make the ratio of total intensities for both dyes equal to one. After normalizing the fluorescence measurements then it was possible to look for changes in gene expression. Criteria for evaluating changes in gene expression vary from study to study however typically three criteria are required:
  • yeast cells were stressed using either ozone or hydrogen peroxide.
  • One set of yeast cells was exposed to 0.002 millimole (0.01 mg/L) of ozone for approximately one hour, while another set of yeast cells was exposed to 0.002 millimole (0.01 mg/L) of hydrogen peroxide for approximately one hour.
  • Analysis of the genes that were subsequently affected by the stress were compared against untreated controls to determine which genes were up-regulated and down-regulated using the criteria defined above.
  • up-regulation or “up-regulated” implies that the gene is over-expressing RNA.
  • down-regulation or “down-regulated” implies RNA is being under-expressed.
  • Yeast that was treated with ozone showed up-regulation of 570 genes and down-regulation of 342 genes.
  • Yeast that was treated with hydrogen peroxide showed up-regulation of 502 genes and down-regulation of 57 genes.
  • yeast genome present on the microarray 570 genes were up-regulated in ozone-stressed yeast with 148 (26%) of them being different than those up-regulated by hydrogen peroxide. Likewise, of the 502 genes up-regulated by hydrogen peroxide, 80 (15.0%) were different than those up-regulated for ozone stressed yeast.
  • GAPDH was up-regulated in the presence of ozone, while it was not affected by hydrogen peroxide consistent with the earlier published scientific studies discussed above.
  • results from ozone exposure of water, non-ozone-stressed yeast lysate and ozone treated yeast lysate are shown in the photograph in FIG. 1 .
  • the ozone-stressed yeast lysate showed increased protection against the oxidizing power of ozone and less degradation to indigo potassium indigo trisulfonate compared to water and nontreated yeast lysate. This study suggests that ozone-stressed yeast lysate contains protective agents to retard the degradation of indigo dye.
  • FIG. 1 shows the visual differences among the four samples. The first jar in the photograph, labeled “control”, contains water and the indigo dye.
  • the control jar does not contain yeast or yeast lysates and the solution in this jar was not subjected to ozone treatment.
  • the second jar labeled “water”, contains water and the indigo dye.
  • This jar also does not contain yeast or yeast lysate, however the solution in this jar was subjected to an ozone treatment to show how the ozone reacts with the indigo dye.
  • the third jar labeled “ozone treated yeast”, contains ozone-stressed yeast lysate in addition to water and the indigo dye.
  • the solution in this jar was subjected to ozone treatment to show how the ozone reacts with the indigo dye in the presence of ozone-stressed yeast lysate.
  • the fourth jar labeled “non-treated yeast”, contains non-ozone-stressed yeast lysate in addition to water and the indigo dye.
  • the solution in this jar was also subjected to ozone treatment to show how the ozone reacts with the indigo dye in the presence of non-ozone-stressed yeast lysate.
  • the indigo reagent is reactive to ozone; adding yeast lysate to the water and indigo dye solution provides some protection to the indigo dye from ozone degradation; and adding ozone-stressed yeast lysate to the water and indigo dye solution provides additional protection to the indigo dye from ozone degradation.
  • Samples of the ozone-stressed yeast lysates were incorporated into a liposome comprising phospholipid and lecithin obtained from soybeans.
  • the lysate was slurried together with the phospholipid and lecithin components and the mixture was homogenized using a high-pressure homogenizer obtained from Hydraulic Engineering Corporation (Brea, Calif.).
  • the milky white mixture contained the ozone-stress yeast lysate encapsulated with the liposomal components.
  • This example illustrates a high internal phase water-in-oil emulsion incorporating the ozone-stressed yeast lysate prepared as disclosed in Example 1.
  • Ingredient wt % 1,3-dimethyl-2-imidazolidinone 0.2 polyoxyethylene (2) oleyl ether 1 5.0 Bentone 38 0.5 MgSO 4 .7H 2 O 0.3
  • Preservative 2 0.01
  • Brij 92 is polyoxyethylene (2) oleyl ether. 2
  • Such as an aldehyde-releasing agent for example DMDM Hydantoin.
  • This example illustrates an oil-in-water cream incorporating the ozone-stressed yeast lysate prepared as disclosed in Example 1.
  • Ingredient wt % Mineral Oil 4 1,3-dimethyl-2-imidazolidinone 1 cetyl alcohol POE (10) 1 4 cetyl alcohol 2 4 Triethanolamine 0.75 Butane-1,3-diol 3 Xanthan gum 0.3 Methyl, Propyl and Butyl Paraben 0.01 Ozone-Stressed Yeast Lysate 10.0 Water to 100 1
  • Brij 56 is cetyl alcohol POE (10) 2
  • Alfol 16RD is cetyl alcohol
  • This example illustrates an alcoholic lotion incorporating a ozone-stressed yeast lysate prepared as disclosed in Example 1.
  • This example illustrates a sub-micron emulsion concentrate that contains a ozone-stressed yeast lysate prepared as described in Example 3.
  • Ingredient wt % Trimethylolpropane Tricaprylate/Tricaprate 18.0 Glycerin 8.0 Cetearyl alcohol 2.0 Ceteareth 20 2.0 Glyceryl stearate 2.0 BHT 0.01 Ozone-Stressed Yeast Lysate 10.0 Water to 100

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US11/248,522 2004-10-13 2005-10-12 Personal care composition containing ozone-stressed yeast lysates Abandoned US20060110815A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US11/248,522 US20060110815A1 (en) 2004-10-13 2005-10-12 Personal care composition containing ozone-stressed yeast lysates
JP2007536849A JP5687817B2 (ja) 2004-10-13 2005-10-13 オゾンストレス付与酵母溶解物を含有するパーソナルケア用組成物
PCT/US2005/036717 WO2006044482A2 (en) 2004-10-13 2005-10-13 Personal care composition containing ozone-stressed yeast lysates
EP05810335.9A EP1807828B1 (de) 2004-10-13 2005-10-13 Körperpflegezusammensetzung mit lysaten ozonbelasteter hefe
JP2013154099A JP2013224328A (ja) 2004-10-13 2013-07-25 オゾンストレス付与酵母溶解物を含有するパーソナルケア用組成物
US15/236,355 US10285933B2 (en) 2004-10-13 2016-08-12 Personal care composition containing ozone-stressed yeast lysates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61869804P 2004-10-13 2004-10-13
US11/248,522 US20060110815A1 (en) 2004-10-13 2005-10-12 Personal care composition containing ozone-stressed yeast lysates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/236,355 Continuation US10285933B2 (en) 2004-10-13 2016-08-12 Personal care composition containing ozone-stressed yeast lysates

Publications (1)

Publication Number Publication Date
US20060110815A1 true US20060110815A1 (en) 2006-05-25

Family

ID=36203491

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/248,522 Abandoned US20060110815A1 (en) 2004-10-13 2005-10-12 Personal care composition containing ozone-stressed yeast lysates
US15/236,355 Expired - Fee Related US10285933B2 (en) 2004-10-13 2016-08-12 Personal care composition containing ozone-stressed yeast lysates

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/236,355 Expired - Fee Related US10285933B2 (en) 2004-10-13 2016-08-12 Personal care composition containing ozone-stressed yeast lysates

Country Status (4)

Country Link
US (2) US20060110815A1 (de)
EP (1) EP1807828B1 (de)
JP (2) JP5687817B2 (de)
WO (1) WO2006044482A2 (de)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021532A1 (en) * 2008-07-24 2010-01-28 Smitha Rao Personal care composition containing yeast/polyphenol ferment extract
US20110044919A1 (en) * 2007-08-15 2011-02-24 Giacomoni Paolo U Compositions With Perfluorinated Ingredients
US20110052517A1 (en) * 2009-08-31 2011-03-03 Avon Place Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions
WO2013060771A2 (en) 2011-10-25 2013-05-02 Arch Personal Care Products, L.P. Composition containing an extract of a sequential or simultaneous fermentation
US20140065086A1 (en) * 2012-08-30 2014-03-06 Avon Products, Inc. Dickkopf-1 Expression Modulating Compositions and Uses Thereof
US20140127257A1 (en) * 2011-06-29 2014-05-08 Evonik Degussa Gmbh Dermatologically effective yeast extract

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008120792A (ja) * 2006-10-16 2008-05-29 Hayashibara Biochem Lab Inc 保湿・整髪作用を有する皮膚及び毛髪用化粧料とその製造方法
KR101865181B1 (ko) * 2011-11-24 2018-06-08 (주)아모레퍼시픽 피부 활력 증진용 화장료 조성물
JP6374991B2 (ja) * 2014-06-13 2018-08-15 ザ プロクター アンド ギャンブル カンパニー トリートメント組成物を角質表面に付着させるためのカートリッジ
US10952936B2 (en) * 2015-12-11 2021-03-23 Dow Global Technologies Llc Concentrated polyolefin emulsions and personal care compositions containing them

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2239345A (en) * 1939-06-19 1941-04-22 Inst Divi Themae Foundation Proliferation stimulants and process of making same
US4540571A (en) * 1981-10-01 1985-09-10 Dr. Babor Gmbh & Co. Cosmetic agent containing natural yeast cell contents
US5019391A (en) * 1987-06-26 1991-05-28 Heyl Chemisch-Parmazeutische Fabrik Gmbh & Co Kg Skin treating composition, method of producing the same and treatment of skin therewith
US5057320A (en) * 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US5514591A (en) * 1988-02-23 1996-05-07 Levin; Robert H. Method for measuring the ability of a yeast cell extract to influence oxygen respiration
US5643587A (en) * 1996-02-15 1997-07-01 Avon Products, Inc. Composition and method for under-eye skin lightening
US5650140A (en) * 1995-07-19 1997-07-22 Church & Dwight Co., Inc. Deodorant cosmetic stick product
US5776441A (en) * 1996-08-30 1998-07-07 Avon Products, Inc. Lip treatment containing live yeast cell derivative
US6103246A (en) * 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US6461857B1 (en) * 2000-07-19 2002-10-08 Arch Personal Care Products, L.P. Producing water-soluble yeast extract by adding peroxide to growing yeast cells
US20030215407A1 (en) * 2002-05-01 2003-11-20 Marvin Klein Composition for treatment of skin and method for stabilizing the composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215609A (ja) 1984-04-09 1985-10-29 Ichimaru Fuarukosu Kk メラノイジン含有皮膚化粧料
JP2989676B2 (ja) * 1991-02-05 1999-12-13 サッポロビール株式会社 酵母エキス抽出残渣の脱色・脱臭方法
AU3270200A (en) 1999-03-31 2000-10-23 Pentapharm Ag Composition for cosmetic and dermatological skin care
JP4754676B2 (ja) * 1999-07-19 2011-08-24 独立行政法人科学技術振興機構 環境ストレス耐性遺伝子
US6521668B2 (en) 1999-12-14 2003-02-18 Avon Products, Inc. Cosmetic composition and methods of use
DE10032964B4 (de) 2000-07-06 2017-10-12 Beiersdorf Ag Verwendung von Kreatin in kosmetischen oder dermatologischen Zubereitungen
US20030198682A1 (en) * 2002-02-12 2003-10-23 Gruber James V. Composition and method for protecting labile active components during high temperature drying
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US6755866B2 (en) 2002-08-20 2004-06-29 Depuy Products, Inc. Prosthetic stem with bearings
CN1921823A (zh) * 2004-03-11 2007-02-28 株式会社资生堂 抗老化剂和胶原产生促进剂

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2239345A (en) * 1939-06-19 1941-04-22 Inst Divi Themae Foundation Proliferation stimulants and process of making same
US4540571A (en) * 1981-10-01 1985-09-10 Dr. Babor Gmbh & Co. Cosmetic agent containing natural yeast cell contents
US5019391A (en) * 1987-06-26 1991-05-28 Heyl Chemisch-Parmazeutische Fabrik Gmbh & Co Kg Skin treating composition, method of producing the same and treatment of skin therewith
US5514591A (en) * 1988-02-23 1996-05-07 Levin; Robert H. Method for measuring the ability of a yeast cell extract to influence oxygen respiration
US5057320A (en) * 1988-08-01 1991-10-15 Nutrition 21 Means and method for increasing skin respiration
US6103246A (en) * 1993-06-03 2000-08-15 Tisdale; Carrie J. Creams and lotions containing emu oil
US5650140A (en) * 1995-07-19 1997-07-22 Church & Dwight Co., Inc. Deodorant cosmetic stick product
US5643587A (en) * 1996-02-15 1997-07-01 Avon Products, Inc. Composition and method for under-eye skin lightening
US5676956A (en) * 1996-02-15 1997-10-14 Avon Products, Inc. Composition and method for reducing under-eye puffiness
US5776441A (en) * 1996-08-30 1998-07-07 Avon Products, Inc. Lip treatment containing live yeast cell derivative
US6461857B1 (en) * 2000-07-19 2002-10-08 Arch Personal Care Products, L.P. Producing water-soluble yeast extract by adding peroxide to growing yeast cells
US20030215407A1 (en) * 2002-05-01 2003-11-20 Marvin Klein Composition for treatment of skin and method for stabilizing the composition

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110044919A1 (en) * 2007-08-15 2011-02-24 Giacomoni Paolo U Compositions With Perfluorinated Ingredients
US20100021532A1 (en) * 2008-07-24 2010-01-28 Smitha Rao Personal care composition containing yeast/polyphenol ferment extract
US9376659B2 (en) 2008-07-24 2016-06-28 Arch Personal Care Products, L.P. Personal care composition containing yeast/polyphenol ferment extract
US9744121B2 (en) 2008-07-24 2017-08-29 Arch Personal Care Products, L.P. Personal care composition containing yeast/polyphenol ferment extract
US20110052517A1 (en) * 2009-08-31 2011-03-03 Avon Place Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions
US8575106B2 (en) 2009-08-31 2013-11-05 Avon Products, Inc. Cosmetic uses of modified stressed yeast extracts and related compositions
US20140127257A1 (en) * 2011-06-29 2014-05-08 Evonik Degussa Gmbh Dermatologically effective yeast extract
US9655934B2 (en) * 2011-06-29 2017-05-23 Evonik Degussa Gmbh Dermatologically effective yeast extract
WO2013060771A2 (en) 2011-10-25 2013-05-02 Arch Personal Care Products, L.P. Composition containing an extract of a sequential or simultaneous fermentation
US20140065086A1 (en) * 2012-08-30 2014-03-06 Avon Products, Inc. Dickkopf-1 Expression Modulating Compositions and Uses Thereof
US9023327B2 (en) * 2012-08-30 2015-05-05 Avon Products, Inc. DICKKOPF-1 expression modulating compositions and uses thereof

Also Published As

Publication number Publication date
WO2006044482A2 (en) 2006-04-27
JP5687817B2 (ja) 2015-03-25
JP2008520549A (ja) 2008-06-19
EP1807828A4 (de) 2010-12-08
EP1807828A2 (de) 2007-07-18
US10285933B2 (en) 2019-05-14
JP2013224328A (ja) 2013-10-31
US20160346195A1 (en) 2016-12-01
WO2006044482A3 (en) 2007-11-08
EP1807828B1 (de) 2016-12-14

Similar Documents

Publication Publication Date Title
US10285933B2 (en) Personal care composition containing ozone-stressed yeast lysates
US9901538B2 (en) Personal care composition containing yeast/polyphenol ferment extract
EP2419438B1 (de) Ein peptidhydrolysat, das die barrierefunktion unterstützen kann, enthaltende kosmetische und/oder pharmazeutische zusammensetzung
EP0899330B1 (de) Aus dem Epidermis isolierte Polypeptide und Verwendung davon
KR100844914B1 (ko) 탄력섬유형성의 불완전, 결여 혹은 해체로 인한 질병을제어하는 라이실 옥시다제의 동종효소의 활성 촉진
EP2421884B1 (de) Peptidhydrolysat als proteasomaktivator und zusammensetzungen, die dieses enthalten
US6461857B1 (en) Producing water-soluble yeast extract by adding peroxide to growing yeast cells
US8226956B2 (en) Extract of R. miehei
JP2011520768A (ja) 皮膚のバリア機能を改善するための、ｆｎ３ｋおよび／またはｆｎ３ｋｒｐの発現を刺激するための有効薬剤の化粧上の使用
KR101601024B1 (ko) 소나무 뿌리 추출물을 함유하는 피부 외용제 조성물
WO1998043607A1 (fr) Compositions cosmetiques amincissantes
WO2010098595A2 (en) Composition for skin external applicationcontaining red pine root extract
JP7024004B2 (ja) 角栓形成予防・改善剤のスクリーニング方法
EP1454633B1 (de) Topisch applizierbare kosmetische oder pharmazeutische Zusammensetzung zur Prävention oder Behandlung androgener Alopezie
JP2013512681A (ja) 皮膚のバリア機能を改善するためのｃｅｒｔの発現を刺激する活性薬剤をスクリーニングするための方法
JP2022046795A (ja) 角栓形成予防・改善剤のスクリーニング方法
JP2022064914A (ja) 角栓形成予防・改善剤のスクリーニング方法
CN115990126A (zh) 一种具有抗糖化、抗氧化、抗炎作用的护肤组合物及其制备方法
Yarosh Enhancement of repair of UV damage in humans

Legal Events

Date Code Title Description
AS Assignment

Owner name: ARCH PERSONAL CARE PRODUCTS, L.P., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRUBER, JAMES VINCENT;REEL/FRAME:017103/0793

Effective date: 20060130

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE